Core Viewpoint - The Kelmė wind farm II has commenced commercial operations, contributing to the largest wind farm in the Baltics, with significant investments and capacity to meet the electricity needs of Lithuanian households [1][2]. Group Summary - Kelmė wind farm II, along with Kelmė wind farm I, forms the largest wind farm in the Baltics, with a total installed capacity of 313.7 MW, capable of supplying electricity to 250,000 households [2]. - The total investment for the Kelmė wind farm, including both wind farms, is approximately EUR 550 million [2]. - Kelmė wind farm II consists of 28 Nordex N163/6.X wind turbines, with a total installed capacity of 199.6 MW, and the investment for this specific wind farm is around EUR 360 million [3]. - Following the commercial operation date of Kelmė wind farm II, the Group's installed Green Capacities have increased to 1.7 GW, up from 1.5 GW [3]. - The Group aims to expand its Green Capacities from 1.4 GW in 2024 to a target range of 4–5 GW by 2030 [4].

Core Points - AKWEL has postponed its Annual General Meeting until after June 30, 2025, due to the ongoing finalization of the audit for the 2024 annual financial statements [2][3] - The company will file a request for postponement with the Commercial Court of Bourg-en-Bresse and will communicate the new schedule to the market as soon as possible [3] - The next press release regarding first-half 2025 sales is scheduled for July 24, 2025, after the close of trading [4] Company Overview - AKWEL is a systems supplier to the automotive and truck industries, specializing in fluid management, mechanisms, and structural parts for electric vehicles [2][4] - The company is independent and family-owned, listed on Euronext Paris, and employs approximately 8,600 people across 20 countries on five continents [4][5] - AKWEL possesses advanced industrial and technological expertise in the application and transformation of materials such as plastic, rubber, and metal, as well as in mechatronics integration [4]

Core Insights - Vallourec has achieved the official qualification of its Delphy hydrogen storage solution, marking a world first in the industry [1][3] - The Delphy system can store between 1 to 100 tons of hydrogen safely and is designed for complex industrial environments [1][2] - The qualification by DNV ensures the safety and reliability of the Delphy solution, paving the way for its commercialization [3][6] Company Developments - The Delphy project has involved around thirty researchers and experts, focusing on high-precision threading, heat treatment, and non-destructive testing [3] - Vallourec has signed two Memorandums of Understanding (MoUs) for green hydrogen projects, indicating strong market interest and potential revenue of approximately €2 billion from around fifty projects under discussion [4] - The company aims to leverage its industrial and technological expertise to support the global hydrogen sector and decarbonization efforts [6] Industry Context - There is an increasing demand for hydrogen storage infrastructure due to the intermittent nature of green hydrogen production, driven by European regulations and the French hydrogen strategy [5] - DNV's Energy Transition Outlook projects a need for 188 million tons of hydrogen annually by 2050, highlighting the critical role of flexible storage solutions like Delphy [6]

VALNEVA Declaration of shares and voting rights May 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: June 5, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recogni ...

Core Insights - Basilea Pharmaceutica Ltd announced a milestone payment of USD 2.5 million due to strong sales performance of its antifungal Cresemba in the Asia Pacific region and China [1][2] - Cresemba's global in-market sales reached USD 562 million in 2024, reflecting a 19% year-on-year growth, establishing it as the largest branded antifungal for invasive fungal infections worldwide [3] Company Overview - Basilea is a commercial-stage biopharmaceutical company founded in 2000, focused on developing innovative drugs for severe bacterial and fungal infections [5] - The company has successfully launched two hospital brands: Cresemba for invasive fungal infections and Zevtera for bacterial infections [5] Product Information - Cresemba (isavuconazole) is available in over 70 countries and is approved in China for treating adult patients with invasive aspergillosis and invasive mucormycosis [4] - The license agreement for Cresemba includes coverage for Europe (excluding Nordic countries), China, and 16 countries in the Asia Pacific region [2]

Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company announced the presentation of preclinical data for its GABAB positive allosteric modulator cough program at the 10th American Cough Conference [1][2] Company Overview - Addex's lead drug candidate is dipraglurant, a negative allosteric modulator targeting mGlu5, currently under evaluation for brain injury recovery [4] - The company is advancing an independent GABAB PAM program specifically for chronic cough, while also collaborating with Indivior on a GABAB PAM drug candidate for substance use disorders [4] - Addex holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs for various neurological conditions [4] Presentation Details - The presentation will be led by Mikhail Kalinichev, Head of Translational Science, discussing the antitussive efficacy of Compound A in guinea pig models [2][3] - The presentation is scheduled for June 7, 2025, at 11:20 am EST [7] Scientific Background - GABAB receptors are crucial in the cough neural circuit and are activated by the neurotransmitter GABA [3] - Current treatments like baclofen have limitations, and targeting allosteric sites may offer advantages such as higher selectivity and better tolerability [3]

Company Expansion - Planisware has opened a new office in Belgium as part of its international expansion strategy in the Benelux region [1][5] - The company has experienced significant growth in the Benelux market, with revenue doubling over the last four years [2] Market Presence - Planisware has been active in the Benelux region for several years, working with major clients such as Galapagos, KLM, Philips, and Engie [2] - The Benelux region is characterized by approximately 1,200 target companies, with nearly half generating annual revenues exceeding one billion euros, particularly in sectors like manufacturing, retail, and financial services [3] Strategic Goals - The new office aims to enhance proximity to customers and local economic players, thereby accelerating new business opportunities and supporting sustainable growth [4] - The CEO emphasized that the expansion into Belgium is a key milestone in the company's growth strategy, reinforcing existing customer relationships and creating local jobs [5] Leadership - The new subsidiary will be led by Benoît Soulier, who has over seven years of project management experience at Planisware and a strong background in managing complex portfolios [5] Company Overview - Planisware is a leading B2B provider of SaaS solutions in the Project Economy, serving around 600 clients across more than 30 countries [6][7]

Core Insights - Burckhardt Compression achieved record financials in fiscal year 2024, surpassing CHF 1 billion in sales and CHF 100 million in net income for the first time, reflecting strong positioning in markets aligned with global megatrends [1][2][3] Financial Performance - Order intake for the Group reached CHF 1,151.2 million, a 2.4% increase, with sales up 12.6% to CHF 1,095.6 million, driven by an 18.2% growth in the Systems Division [2][5] - Gross profit margin improved to 28.0%, up 1.8 percentage points year-on-year, due to a favorable product mix and higher capacity utilization [2] - Consolidated operating income (EBIT) increased by 23.2% to CHF 140.8 million, with an overall Group EBIT margin rising to 12.9% from 11.7% [2][5] Profitability and Returns - Net income reached CHF 105.6 million, exceeding the previous year's figure by 25.0%, with earnings per share rising from CHF 24.98 to CHF 31.20 [3][4] - Return on Net Operating Assets (RONOA) increased from 28.3% to 32.6%, and total equity rose to CHF 340.2 million [4] Dividend Proposal - The Board of Directors proposed a dividend of CHF 18.00 per share, marking a 16.1% increase compared to the previous year, aligning with the Group's attractive dividend policy [4] Market Dynamics - The global Systems market normalized in 2024, with a decrease driven by policy shifts in the Hydrogen Mobility and Energy segment, while demand for Hyper Compressors remained high [5][7] - The Services Division experienced a 5.4% decline in order intake to CHF 325.8 million, influenced by local economic conditions and the closure of low-profit service centers in the US [8] Strategic Initiatives - Burckhardt Compression is implementing its Mid-Range Plan, focusing on strengthening core business, operational excellence, and enhancing business foundations, including a 40.0% reduction in greenhouse gas emission intensity [9][14] - New digital services were launched to optimize compressor fleet reliability and uptime, contributing to the company's transformation efforts [9] Leadership Changes - Upcoming changes in the Board of Directors include the proposal of Jacques Sanche as a new member and Chair, effective December 15, 2025, following Ton Büchner's planned succession [10][11] Guidance for Fiscal Year 2025 - The company expects fiscal year 2025 to maintain sales and EBIT margins at similar levels to fiscal year 2024, amid a dynamic operating environment characterized by uncertainties in global trade and currency exchange rates [12][13]

Core Viewpoint - Helius Medical Technologies, Inc. has announced a public offering of 2,768,600 shares of Class A common stock and accompanying warrants, priced at $3.27 per share, aiming to raise approximately $9.1 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The public offering includes 2,768,600 shares of Class A common stock and warrants to purchase an equal number of shares at a combined price of $3.27 per share [1]. - Each warrant will expire in 2.5 years from issuance, is immediately exercisable at an initial price of $7.3575 per share, and can be exchanged for 2.0 common shares under a zero cash exercise option [2]. - The offering is expected to close on June 6, 2025, subject to customary closing conditions [3]. Group 2: Regulatory and Contact Information - A registration statement on Form S-1 was filed with the SEC and declared effective on June 4, 2025, with a final prospectus to be available on the SEC's website [4]. - Electronic copies of the prospectus can be obtained from Maxim Group LLC, the sole placement agent for the offering [4][7].

Core Points - Vortex Energy Corp. has announced the conversion of outstanding unsecured convertible debentures following notices of conversion from all holders [1] - The company issued the debentures on January 28, 2025, for a total principal amount of C$400,000, with accrued interest resulting in a total payable amount of C$413,916.36 [2] - To satisfy this amount, Vortex will issue 1,061,324 units at a conversion price of C$0.39 per unit, each unit consisting of one common share and one warrant [3] Company Overview - Vortex Energy Corp. is engaged in the acquisition, exploration, and development of mineral properties in North America, focusing on the Robinson River Salt Project and the Fire Eye Uranium Property [5]